Are psychedelics set to follow cannabis into mainstream medical acceptance?

Psychedelics are having another moment in the spotlight. But they’ve evolved since their notoriety of the 1960s, when they were portrayed as they way to “turn on, tune in and drop out” of society.

Today’s focus is on their ability to ease a range of mental health conditions, from PTSD to OCD, and this quality has been the subject of newspaper headlines, New York Times bestsellers and Netflix documentaries.

But is all this heightened awareness just hype, or have these once-taboo substances been permanently rehabilitated? And does this make them a good business prospect that could follow a similar trajectory to that of the cannabis industry: recognition of their therapeutic benefits leading to regulatory approval and then widespread public acceptance?

Read full article
I'm already a subscriber
Author default picture

Lorraine Mullaney

Senior writer
Lorraine is responsible for writing news analysis and assisting with copy-editing. Lorraine is a copywriter and editor who has written and edited words for a wide range of audiences, from local community newspapers to consumer magazines and trade websites.